How RMS and CMS Roles Work Together in MRP and DCP

Introduction

The Reference Member State (RMS) and Concerned Member States (CMSs) are two complementary parts of the regulatory structure used for the mutual recognition procedure (MRP) and decentralised procedure (DCP).

The RMS leads the assessment and coordinates the procedure. The CMSs participate in the scientific and regulatory review and, following the applicable procedure, grant or maintain national marketing authorisations in their territories.

The relationship is therefore more accurately understood as coordinated regulatory work between national competent authorities than as a hierarchy in which the RMS acts as the regulator of the CMSs.

Dedicated articles in this series explain what an RMS is and what a CMS is. This article addresses the relationship between them: how work is divided, how information moves between the authorities, how agreement is reached, and what happens when agreement cannot be reached.

A simplified model is:

                    Applicant
                       |
                       v
              +----------------+
              |      RMS       |
              | Lead assessment|
              |  Coordination  |
              +-------+--------+
                      |
             assessment / issues
                      |
          +-----------+-----------+
          |                       |
          v                       v
    +-----------+           +-----------+
    |   CMS 1   |           |   CMS 2   |
    | Review /  |           | Review /  |
    | comments  |           | comments  |
    +-----------+           +-----------+
          |                       |
          +-----------+-----------+
                      |
                      v
               Common outcome
                      |
                      v
              National MAs

The precise procedural steps depend on whether the procedure is an MRP or DCP and on the applicable legislation and guidance. The model above is therefore a conceptual framework rather than a substitute for the procedure-specific legal requirements.

1. Why the RMS/CMS Relationship Exists

MRP and DCP allow several Member States to participate in the assessment of a medicinal product while avoiding a completely independent scientific assessment of the same dossier by every authority.

A central principle is that regulatory authorities should be able to rely on a common scientific assessment while retaining their responsibilities under the applicable national and Union framework.

The RMS provides the principal assessment and coordination function. CMSs review that work and participate in reaching the common regulatory position.

This arrangement creates two important properties at the same time:

• coordination, because the authorities work from a common assessment framework; and
• independent regulatory responsibility, because each participating national authority remains part of the national authorisation system.

The system would not work effectively if every CMS simply repeated the RMS assessment from the beginning. It would also not work if CMSs were expected to accept every RMS conclusion without scientific review.

The relationship is designed to operate between those extremes.

2. RMS and CMS Are Roles Within a Procedure

RMS and CMS should not be interpreted as permanent classifications attached to a Member State.

The designation is linked to a particular procedure.

For one procedure, for example:

France      = RMS
Germany     = CMS
Spain       = CMS
Netherlands = CMS

For another procedure, Germany could be the RMS and France could be a CMS.

Consequently, a regulatory system should record the RMS/CMS designation at the procedure and product level rather than treating it as a fixed attribute of a national authority.

This also explains why the same competent authority can have different procedural responsibilities across its portfolio.

3. The Division of Work

At a high level, the division can be described as follows:

The table is intentionally high level. It should not be read as assigning every procedural communication or document exclusively to one side. The applicable procedural guidance determines the detailed mechanics.

The central distinction is that the RMS leads and coordinates, whereas the CMSs review, contribute and retain their national regulatory responsibilities.

4. The RMS Assessment Is the Common Starting Point

The RMS prepares the principal scientific assessment for the procedure.

That assessment gives the CMSs a common reference against which to review the application.

The objective is not merely administrative consistency. A common scientific assessment can reduce duplication and allow substantive regulatory discussion to focus on areas where interpretation, evidence or regulatory conclusions require further consideration.

The RMS assessment therefore needs to be sufficiently reasoned to permit meaningful review by the CMSs.

A weak assessment would make the coordinated procedure difficult because CMSs would have to reconstruct the scientific reasoning themselves. A clear assessment gives the participating authorities a common analytical framework.

5. CMS Review Is More Than Formal Endorsement

CMS participation should not be understood as a ceremonial endorsement of the RMS assessment.

CMSs review the scientific and regulatory conclusions within the applicable procedure and may raise questions, request clarification or identify concerns.

This is an important safeguard in the system.

The fact that one competent authority has led an assessment does not remove the responsibility of the other participating authorities to consider whether the resulting regulatory position is acceptable under the applicable framework.

The resulting dialogue may concern:

• interpretation of clinical evidence;
• quality considerations;
• safety findings;
• benefit-risk conclusions;
• product information;
• risk-management measures;
• or other regulatory matters within the scope of the procedure.

6. How the Common Regulatory Position Develops

The procedure can be viewed as an iterative exchange rather than a one-way transmission of the RMS assessment.

RMS assessment
      |
      v
CMS review
      |
      v
Questions / comments
      |
      v
RMS / applicant assessment and response
      |
      v
Updated regulatory position
      |
      v
Further CMS review where required
      |
      v
Agreement

The applicant is also part of this process. Regulatory questions are not simply exchanged between authorities; the applicant provides the evidence, explanations and proposed changes needed to address the issues raised during assessment.

The RMS then coordinates the assessment of those responses within the procedure.

7. The Applicant Sits Between Scientific Evidence and Regulatory Coordination

The applicant should not manage communication with the RMS and CMSs as though they were unrelated national negotiations.

The dossier and scientific position should remain coherent across participating Member States.

At the same time, the applicant must distinguish between:

• the common scientific and regulatory position;
• procedural communications;
• national implementation requirements; and
• genuinely national matters that remain outside the common assessment.

This distinction becomes particularly important after the common procedure concludes, because the resulting marketing authorisations remain national.

8. Why Coordination Does Not Eliminate National Responsibility

MRP and DCP are coordinated procedures under a common EU legal framework, but they do not transform participating national competent authorities into a single regulatory authority.

The RMS does not issue a single EU-wide marketing authorisation for the product merely by leading the assessment.

Likewise, CMSs do not become subordinate offices of the RMS.

The common assessment supports coordinated national regulatory action.

This distinction is fundamental to understanding why the same regulatory history can contain both a common European procedure and separate national marketing authorisations.

9. RMS and CMS Communication Should Be Traceable

From a regulatory-affairs perspective, the quality of communication between RMS, CMSs and the applicant is part of the procedural control environment.

Important communications should allow a later reviewer to determine:

• what issue was raised;
• who raised it;
• what evidence was considered;
• what response was provided;
• what conclusion was reached;
• and how that conclusion affected the regulatory position.

This becomes especially valuable when a product changes hands between regulatory teams or when a later variation or safety procedure requires reconstruction of the earlier regulatory reasoning.

10. The Difference Between Scientific Agreement and Administrative Completion

A procedure should not be considered scientifically resolved merely because documents have been exchanged or an administrative milestone has been reached.

The important question is whether the substantive regulatory issues have been addressed sufficiently for the applicable procedure to reach its next stage.

This distinction matters particularly where CMSs have raised concerns about safety or benefit-risk.

An administrative event can be recorded objectively. Scientific agreement requires an assessment of the substance of the issue.

11. When a CMS Raises a Serious Concern

A CMS may raise a concern that cannot simply be treated as another drafting comment.

For example, a concern may relate to a potential serious risk to public health within the meaning of the applicable legal framework.

At that point, the RMS/CMS relationship changes from routine coordination to formal disagreement management.

The CMS should substantiate the concern, and the procedure provides mechanisms for attempting to resolve the disagreement.

The dedicated article What Happens When Member States Disagree During an MRP or DCP? examines this pathway in detail.

The important point here is the boundary:

The RMS leads the common procedure, but it cannot simply erase a substantive CMS objection by virtue of being the RMS.

12. RMS/CMS Interaction and Product Information

Product information is one of the most visible outputs of the coordinated assessment.

The RMS and CMSs need to work toward an agreed regulatory position concerning the applicable product information.

Questions may concern:

• indications;
• contraindications;
• warnings and precautions;
• adverse reactions;
• posology;
• special populations;
• risk-minimisation measures.

The scientific reasoning behind these elements should be consistent with the underlying assessment.

A change to the wording of product information should therefore not be treated as a purely editorial exercise when the change reflects a substantive scientific conclusion.

13. Pharmacovigilance Interfaces

The RMS/CMS relationship also has significance after authorisation.

Safety information generated during the product lifecycle may require regulatory action affecting nationally authorised products established through MRP or DCP.

The pharmacovigilance organisation therefore needs to understand:

• which Member State acted as RMS;
• which Member States are CMSs;
• the regulatory history of the product;
• the authorised safety information;
• and the applicable procedure for subsequent safety action.

The QPPV does not become the owner of the MRP or DCP merely because the product is subject to pharmacovigilance. The relevant responsibility is to ensure that the pharmacovigilance system can identify, assess, communicate and implement safety-relevant regulatory information appropriately.

14. The Practical Mental Model

For regulatory professionals, the most useful mental model is:

              COMMON PROCEDURE
                     |
          +----------+----------+
          |                     |
          v                     v
        RMS                    CMSs
   lead / coordinate       review / contribute
          |                     |
          +----------+----------+
                     |
                     v
              Common position
                     |
                     v
             National outcomes

The RMS is the lead coordinator, not a superior authority.

The CMSs are active participants, not passive recipients.

The applicant is responsible for maintaining a coherent scientific and regulatory submission while responding appropriately to the participating authorities.

This division of roles is the foundation for understanding both successful agreement and formal disagreement during MRP and DCP.

Key Takeaways

1. RMS and CMS are procedural roles performed by national competent authorities.
2. The RMS leads the assessment and coordinates the procedure.
3. CMSs actively review the assessment and can raise scientific or regulatory concerns.
4. The RMS is not hierarchically superior to the CMSs.
5. The applicant should maintain one coherent regulatory and scientific position while recognising the national nature of the resulting authorisations.
6. A common assessment reduces unnecessary duplication but does not eliminate national regulatory responsibility.
7. Substantive disagreement, particularly a potential serious risk to public health, follows a specific regulatory pathway.
8. Product information is an important output of the common assessment and should reflect the agreed scientific and regulatory position.
9. Regulatory and pharmacovigilance teams should preserve traceability between scientific evidence, regulatory discussion and the resulting authorised position.
10. Understanding the RMS/CMS relationship is essential for correctly interpreting MRP and DCP files.

References

1. European Parliament and Council. Directive 2001/83/EC on the Community code relating to medicinal products for human use, as amended. Principal legal framework for mutual recognition and decentralised procedures and the roles of participating Member States.
2. CMDh. Current guidance on Mutual Recognition and Decentralised Procedures. Procedural guidance concerning RMS/CMS interaction, assessment, communication and national implementation.
3. European Commission. EudraLex, Volume 2A — Procedures for marketing authorisation. European procedural guidance and Notice to Applicants material.
4. European Medicines Agency. Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh). Current information on CMDh and the coordination of nationally authorised medicines.
5. European Medicines Agency. European regulatory system for medicines. Current explanatory material on the interaction between national competent authorities and the European regulatory network.

Regulatory Note

This article is an educational explanation of the relationship between RMS and CMS roles in EU mutual recognition and decentralised procedures for human medicinal products. It does not replace the current consolidated legislation, CMDh guidance, national competent-authority requirements or procedure-specific regulatory documents.

The dedicated RMS and CMS articles provide more detailed descriptions of the individual roles. The present article deliberately focuses on how those roles interact and therefore avoids reproducing their full individual responsibilities.

Where a live regulatory procedure is being assessed, the applicable legislation and current procedure-specific documents take precedence over this general educational explanation.

15. What the RMS/CMS Relationship Means for Regulatory Handover

A product can remain authorised for many years after its original MRP or DCP. Regulatory teams may change, companies may reorganise, and responsibility for the product may move between functions or organisations.

A well-maintained regulatory history should therefore preserve the relationship between the RMS and CMSs at the time of the original procedure and during relevant subsequent procedures.

A useful handover record should identify:

• the procedure type;
• the procedure number;
• the RMS;
• the participating CMSs;
• the key assessment conclusions;
• significant questions and responses;
• the agreed product information;
• unresolved or subsequently managed issues;
• and important post-authorisation regulatory actions.

This is particularly valuable when a later safety issue requires the organisation to understand the original regulatory context.

16. RMS/CMS Roles in Later Procedures

The RMS/CMS relationship does not disappear when the initial authorisation procedure ends.

For some subsequent regulatory procedures involving nationally authorised medicines, a Member State may again perform a coordinating or reference function under the applicable legal framework.

The exact role depends on the procedure. The original RMS should therefore not automatically be assumed to be the responsible authority for every subsequent regulatory action.

This is an important operational distinction. Regulatory systems should record the authority responsible for each relevant procedure, rather than carrying forward an assumption from the original MRP or DCP.

17. What a Regulatory Professional Should Ask When Reviewing an MRP/DCP

When taking responsibility for an existing product, the following questions provide a practical starting point:

1. What was the original procedure: MRP or DCP?
2. Which Member State acted as RMS?
3. Which Member States participated as CMSs?
4. What was the principal scientific conclusion?
5. Were there significant CMS concerns?
6. How were those concerns resolved?
7. What product information was agreed?
8. Which national marketing authorisations resulted?
9. Have subsequent procedures changed the regulatory position?
10. Is the current regulatory position consistent across the relevant national authorisations?

These questions help distinguish the history of the coordinated procedure from the current legal status of each national authorisation.

18. Example: Why RMS/CMS Distinction Matters

Consider a medicinal product authorised through a DCP in five Member States.

The RMS leads the assessment and the CMSs participate in the procedure. Following completion, national marketing authorisations are granted in the participating Member States.

Several years later, a safety concern emerges.

A regulatory team reviewing the product should not conclude simply that:

"The RMS controls the product in all five countries."

That is the wrong model.

Instead, the team should establish:

• the current legal status in each Member State;
• the applicable pharmacovigilance and regulatory framework;
• whether a common or national procedure is appropriate;
• which authority has the relevant procedural role;
• and whether a Union procedure or coordination mechanism becomes applicable.

The historical RMS remains an important part of the regulatory record, but historical RMS status alone does not determine every future regulatory responsibility.

19. What the RMS/CMS Model Achieves

The RMS/CMS model is one of the mechanisms through which the EU medicines regulatory system combines national authorisation with European regulatory cooperation.

It allows participating authorities to share scientific work and regulatory reliance while retaining their respective legal responsibilities.

The model therefore addresses two competing needs:

Efficiency: avoid unnecessary duplication of scientific assessment.

Regulatory responsibility: allow participating national authorities to perform their functions within the applicable legal framework.

This balance is one reason why understanding the roles of RMS and CMS is more useful than memorising their acronyms alone.

20. Common Errors in Interpreting RMS/CMS Roles

Treating the RMS as a European regulator

The RMS is a national competent authority acting in a defined European procedure. It is not a replacement for EMA or for the European Commission.

Treating CMSs as passive observers

CMSs participate in the assessment and may raise substantive concerns.

Assuming the RMS makes the national decision for CMSs

The coordinated assessment supports national authorisation, but the national competent authorities retain their respective responsibilities.

Treating a historical RMS designation as permanent

RMS designation is procedure-specific. A later procedure may have a different responsible authority.

Assuming agreement means identical administrative records

The scientific and regulatory position may be coordinated while the resulting authorisations remain national records.

Treating product-information wording as independent of scientific assessment

Important wording changes often reflect substantive scientific or regulatory conclusions and should be traceable to their basis.

Assuming every disagreement becomes an Article 29(4) referral

The applicable disagreement pathway depends on the nature and stage of the issue and the governing legislation. A dedicated article addresses the formal disagreement process.

21. Relationship to Article 26: Member State Disagreement

The RMS/CMS relationship is easiest to understand when paired with the next article in this series, What Happens When Member States Disagree During an MRP or DCP?

Routine procedure management is based on assessment, review, discussion and agreement.

A substantive unresolved concern can move the process into a formal disagreement mechanism.

The transition is therefore:

Routine assessment
       ↓
CMS review
       ↓
Questions / concerns
       ↓
Scientific discussion
       ↓
Agreement
       │
       └───────────────┐
                       │ if unresolved qualifying concern
                       ▼
              Formal disagreement
                       ↓
                 Applicable EU
              coordination mechanism

The important regulatory principle is that the RMS/CMS relationship contains a mechanism for challenge and resolution, not merely a mechanism for distributing administrative tasks.

Key Takeaways

1. RMS and CMS roles are complementary rather than hierarchical.
2. The RMS leads and coordinates; CMSs actively review and contribute.
3. The common assessment supports coordinated regulatory action but does not create a single national authority.
4. The applicant must maintain a coherent scientific position while respecting the national nature of the resulting marketing authorisations.
5. RMS and CMS designations should be tracked at the procedure level.
6. The original RMS is not automatically responsible for every later procedure affecting the product.
7. Good regulatory records preserve the reasoning and communication underlying the common regulatory position.
8. Product information should be understood as an output of scientific and regulatory assessment, not merely document formatting.
9. Substantive CMS concerns have defined mechanisms for resolution under the applicable EU framework.
10. The RMS/CMS model illustrates how the EU system combines scientific cooperation with national regulatory responsibility.

References

1. European Parliament and Council. Directive 2001/83/EC on the Community code relating to medicinal products for human use, as amended. Principal legal framework for national marketing authorisation procedures, including mutual recognition and decentralised procedures.
2. European Commission. EudraLex, Volume 2A — Procedures for marketing authorisation. Current procedural guidance and Notice to Applicants material.
3. CMDh. Current guidance on Mutual Recognition and Decentralised Procedures. Procedural guidance concerning RMS/CMS roles, assessment, communication and implementation.
4. European Medicines Agency. Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh). Current information concerning CMDh's coordination role for nationally authorised human medicines.
5. European Medicines Agency. European regulatory system for medicines. Current explanatory material concerning the interaction between national competent authorities and the European regulatory network.
6. European Medicines Agency. Referral procedures for human medicines. Current information concerning Union procedures that may become relevant when Member States cannot resolve certain regulatory disagreements.

Regulatory Note

This article is an educational explanation of how RMS and CMS roles interact during EU mutual recognition and decentralised procedures for human medicinal products. It does not constitute legal advice and does not replace the applicable consolidated legislation, current CMDh guidance, national competent-authority requirements or procedure-specific regulatory documents.

The article deliberately focuses on the relationship between RMS and CMS rather than reproducing the detailed individual-role descriptions provided in the dedicated RMS and CMS articles.

Where a live regulatory issue is being assessed, the applicable legislation and current procedure-specific documents take precedence. Particular care should be taken when determining the legal status of a national marketing authorisation and the competent authority responsible for a subsequent procedure.